No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
AVNS240517P22500
- 3.85
- 0.000.00%
15min DelayTrading Apr 16 14:25 ET
0.00High0.00Low
0.00Open3.85Pre Close0 Volume0 Open Interest22.50Strike Price0.00Turnover41.93%IV0.05%PremiumMay 17, 2024Expiry Date2.96Intrinsic Value100Multiplier9DDays to Expiry0.89Time Value100Contract SizeAmericanOptions Type-0.9998Delta0.0315Gamma6.62Leverage Ratio0.0000Theta-0.0001Rho-6.62Eff Leverage0.0001Vega
Intraday
- 5D
- 1D
News
Express News | JMP Securities Reiterates Market Perform on Avanos Medical
Avanos Medical Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/07/2024 — JMP Securities Reiterates → Market Perform 07/25/2023 — Keybanc Downgrades Overweight → Sec
Analysts' Opinions Are Mixed on These Healthcare Stocks: Enanta Pharmaceuticals (ENTA), OrthoPediatrics (KIDS) and Avanos Medical (AVNS)
Avanos Medical, Inc. (NYSE:AVNS) Q1 2024 Earnings Call Transcript
Earnings Call Summary | Avanos Medical(AVNS.US) Q1 2024 Earnings Conference
The following is a summary of the Avanos Medical, Inc. (AVNS) Q1 2024 Earnings Call Transcript:Financial Performance:Avanos reported Q1 2024 sales from continuing operations at approximately $166 mill
Avanos Medical, Inc. (AVNS) Q1 2024 Earnings Call Transcript
Avanos Medical, Inc. (AVNS) Q1 2024 Earnings Call Transcript
Comments
Recent insider selling of Avanos Medical stock, particularly by Senior VP Michael Greiner, is concerning. Insiders' lack of significant ownership and their share selling could deter potential investors.
This Insider Has Just Sold Shares In Avanos Medical 1
Unresolved challenges may be indicated by weak growth and share price performance. The market's focus is likely on revenue due to the company's lack of profits. Accelerated revenue growth or profits could attract more interest in the stock.
Analysts predict a below-average future growth rate for Avanos Medical despite its high P/E ratio. This warns of a possible risk for investors, who might pay a premium not supported by the earnings outlook.
Read more